Abstract 56P
Background
Hippocampus is associated with formation and storage of new memory and irradiation of same during whole brain radiotherapy in brain metastases leads to decline in the neurocognitive function. Recent advancements in radiation delivery in form of IMRT, Hippocampal avoidance has been made possible. We analyze feasibility of hippocampal sparing and associated neurocognitive and dosimetric assessment.
Methods
Between June 2016 to December 2017, 125 patients diagnosed radiologically and clinically with brain metastases were included in the study. Mini Mental State Examination (MMSE) and quality of life assessment with EORTC BN20 questionnaire were assessed along with dosimetry. Patients were assessed at baseline and followed by at 1, 3 and 6 months respectively. Factors were compared with the historical group with relation to quality of life especially neurocognitive functioning. Wilcoxon test for multiple comparisons was calculated to detect significant differences in global QoL scores.
Results
Median age of accrued 125 patients was 48 years. Median D100% and Dmax to contralateral hippocampus was 7.1Gy and 16.7Gy. With IMRT, the doses to other critical structures were reduced. Patients treated with IMRT were found to have achieved desired dose constraints to hippocampus. Assessment of neurocognitive function between two groups, there was no difference at 1 month after treatment, however, difference was seen at 3 and 6 months favouring hippocampal avoidance. No difference noted in other aspects of quality of life between two groups. No severe toxicities (Grade 3 and 4) were noted in either group. Median survival in the HA-WBRT arm was found to be 10.1 months.
Conclusions
Conformal avoidance of hippocampus during WBRT is associated with improved neurocognitive function and quality of life. IMRT has found to provide better dosimetric outcomes in HA-WBRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract